Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00268905
Status:
COMPLETED
Last Update Posted:
2013-02-12
First Post:
2005-12-21
Brief Title:
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Phase Ib Open-Label Two-Arm Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum tolerated dose MTD and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors
Detailed Description:
This is a Phase Ib open-label two-arm dose-finding study of E7389 in combination with carboplatin in patients with solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None